Xcorporeal Inc represents a strong commitment to innovation, patient care, and technological advancements in the healthcare industry. With a focus on developing novel solutions for renal diseases, Xcorporeal Inc aims to improve the quality of life for patients worldwide. The company's corporate philosophy revolves around integrity, collaboration, and excellence. By leveraging cutting-edge technologies and clinical expertise, Xcorporeal Inc strives to revolutionize renal therapies and provide innovative alternatives to traditional treatments. With a passion for improving patient outcomes, Xcorporeal Inc is dedicated to pushing boundaries and shaping the future of renal care.

Xcorporeal Inc is primarily present in the United States.

Xcorporeal Inc has achieved several significant milestones in its journey. Firstly, the company successfully developed and commercialized the WAK, a wearable artificial kidney, which revolutionized the treatment of end-stage renal disease. This breakthrough innovation enabled patients to lead a more normal lifestyle, reducing long hours spent in dialysis centers. Additionally, Xcorporeal Inc established strategic partnerships with leading healthcare organizations, expanding its reach and ensuring wider adoption of its life-changing technology. Furthermore, the company attained regulatory approvals, indicating the product's safety and efficacy. With each milestone, Xcorporeal Inc continues to make remarkable strides in the medical field, enhancing the quality of life for kidney disease patients worldwide.

Xcorporeal Inc is a medical technology company specializing in the development and commercialization of innovative products for patients suffering from kidney failure. Founded in 2003, Xcorporeal has emerged as a pioneer in the field of extracorporeal therapies, focusing on the advancement of portable dialysis devices. With a commitment to addressing the challenges and limitations of traditional hemodialysis treatments, Xcorporeal aims to provide patients with more freedom and improved quality of life. The company has made significant strides in research, development, and clinical trials, demonstrating its dedication to improving the lives of individuals with kidney failure. Xcorporeal Inc continues to be a driving force in the medical device industry, with a strong focus on innovation and patient-centric solutions.

The main competitors of Xcorporeal Inc in the market include company A, company B, and company C. These companies operate in a similar industry and offer comparable products and services to Xcorporeal Inc. Xcorporeal Inc competes with these companies in terms of market share, product quality, pricing, and innovation. By staying informed about the strategies and advancements of its competitors, Xcorporeal Inc can continue to adapt and differentiate itself within the market.

Xcorporeal Inc is primarily active in the healthcare industry, specifically in the development and commercialization of innovative medical devices. With a focus on providing advanced renal replacement therapies, Xcorporeal Inc aims to improve the quality of life for patients with acute kidney injury and end-stage renal disease. Their portfolio of products includes portable hemodialysis systems that offer flexibility and convenience for patients in various healthcare settings. Xcorporeal Inc is dedicated to addressing the needs of the growing population of individuals with kidney-related conditions, making significant strides in the healthcare industry.

The business model of Xcorporeal Inc. is focused on providing innovative and advanced medical devices and solutions in the field of renal therapy. With a mission to improve the quality of life for patients suffering from kidney failure, Xcorporeal Inc. develops and commercializes portable extracorporeal devices that offer convenient and effective alternatives to traditional dialysis treatments. By leveraging their technological expertise, Xcorporeal Inc. aims to enhance patient care and restore independence by enabling on-the-go hemodialysis solutions. As a leading player in the renal therapy market, Xcorporeal Inc. continues to revolutionize the way kidney failure is managed, offering notable benefits and advancements in the field of healthcare.

KGV untuk Xcorporeal saat ini tidak dapat dihitung.

KUV untuk Xcorporeal saat ini tidak dapat dihitung.

Skor Kualitas AlleAktien untuk Xcorporeal adalah 5/10.

Pendapatan untuk Xcorporeal saat ini tidak dapat dihitung.

Laba saat ini tidak bisa dihitung untuk Xcorporeal.

Xcorporeal Inc. specializes in the development of innovative products and technologies in the field of kidney replacement therapy. It offers various solutions aimed at improving the quality of life for patients with kidney failure, including continuous blood purification and filtration. The business model of Xcorporeal can be divided into three main categories: product manufacturing, technology development, and services. A focus within these areas is on providing HDX technology, a patented system that allows for continuous hemofiltration and dialysis. Product manufacturing involves the development and distribution of medical devices that can be used for the treatment of kidney patients. This includes the HDX system, which enables the continuous exchange of water and electrolytes in the blood, as well as dialyzers that help filter toxins from the patient's blood. The company also offers specialized catheters for accessing the blood circulation. In addition to product manufacturing, Xcorporeal also drives technology development. The company works on advancing its HDX technology to make it more effective and user-friendly. This includes conducting research and development projects in collaboration with other companies and institutions. Finally, Xcorporeal also provides services to facilitate the use of its products. This includes training and educational programs for doctors and medical staff who operate and treat patients with the HDX system. The company also offers consulting services to support patients and medical personnel in selecting and applying the appropriate products. Overall, Xcorporeal operates in the niche industry of kidney replacement therapy and offers a variety of tailored solutions for the needs of kidney patients. With its innovative products and technologies, Xcorporeal has become a key player in this field and contributes to improving patients' quality of life.

Xcorporeal membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Xcorporeal saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Xcorporeal adalah US98400P1049.

WKN dari Xcorporeal adalah A0M297.

Ticker dari Xcorporeal adalah XCRP.

Dalam 12 bulan terakhir, Xcorporeal membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Xcorporeal diperkirakan akan membayar dividen sebesar 0 USD.

Imbal hasil dividen dari Xcorporeal saat ini adalah .

Xcorporeal membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Xcorporeal membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

Xcorporeal dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Xcorporeal tanggal 10/11/2024 sejumlah 0 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 10/11/2024.

Pembayaran dividen terakhir dilakukan pada 10/11/2024.

Pada tahun 2023, Xcorporeal 0 USD telah dibayarkan sebagai dividen.

Dividen dari Xcorporeal dibayarkan dalam USD.